New Jersey is currently home to 1663 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Select Advanced Solid Tumors
Register for Updates
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
NCT03692897
Recruiting
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical q... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey
Conditions: Hepatitis B, Hepatitis, Liver Diseases
Register for Updates
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281
Recruiting
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Advanced Heart Care LLC, Bridgewater, New Jersey
Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Register for Updates
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
NCT04972721
Recruiting
Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial including the trial medicine participants have been taking. When the SELECT trial ends, participants will no longer get the medicine participants got in the study, even if participants decide to take par... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/27/2025
Locations: Master Centre for USA, Plainsboro, New Jersey
Conditions: Overweight, Obesity
Register for Updates
A Study of ERAS-601 in People With Chordoma
NCT06957327
Recruiting
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Chordoma
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Study Site, Mullica Hill, New Jersey
Conditions: Non-Small Cell Lung Cancer
Register for Updates
AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793
Recruiting
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: Research Site, New Brunswick, New Jersey
Conditions: B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL)
Register for Updates
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884
Recruiting
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2025
Locations: Research Site, Hackensack, New Jersey
Conditions: Hepatocellular Carcinoma
Register for Updates
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
NCT05949021
Recruiting
This clinical trial aims to evaluate the efficacy, safety, and exploratory measures of liposomal doxorubicin and carboplatin combination therapy in the adjuvant setting for early stage triple negative breast cancer (TNBC) patients. The primary objective is to determine the effectiveness of liposomal doxorubicin and carboplatin in reducing the risk of recurrence for early stage TNBC patients. The secondary objectives involve characterizing the safety and toxicity profile of the combination ther... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/25/2025
Locations: RWJBarnabas Health - Trinitas hospital and Comprehensive Center, Elizabeth, New Jersey
Conditions: Triple Negative Breast Cancer (TNBC)
Register for Updates
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
NCT05685173
Recruiting
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: B-cell Non-Hodgkins Lymphoma (B-NHL)
Register for Updates
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320
Recruiting
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
Recruiting
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/25/2025
Locations: Atlantic Health System Hospital Corp - Morristown Medical Center, Morristown, New Jersey
Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
Register for Updates